Esperance Pharmaceuticals Inc   Report issue

For profit Phase 2
Founded: Baton Rouge LA United States (2005)
Status: Left NME R&D (2021)

Organization Overview

First Clinical Trial
2009
NCT00949559
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2012

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

ep-100 (2 trials)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma, Ovarian Epithelial (Phase 2)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2